Advertisement
UK markets open in 44 minutes
  • NIKKEI 225

    38,110.28
    -92.09 (-0.24%)
     
  • HANG SENG

    18,498.66
    +184.80 (+1.01%)
     
  • CRUDE OIL

    79.39
    +0.40 (+0.51%)
     
  • GOLD FUTURES

    2,321.90
    -0.40 (-0.02%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • Bitcoin GBP

    49,434.54
    -635.57 (-1.27%)
     
  • CMC Crypto 200

    1,313.13
    +13.03 (+1.00%)
     
  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     
  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     

How This Historic FDA Approval Benefits Viatris

How This Historic FDA Approval Benefits Viatris

U.S. biopharmaceutical company Viatris (NASDAQ: VTRS) and its partner, Indian biopharma Biocon, announced on July 28 that the U.S. Food and Drug Administration (FDA) had approved their biosimilar insulin drug, Semglee, as an "interchangeable biosimilar" -- a direct alternative to Sanofi's (NASDAQ: SNY) blockbuster insulin drug, Lantus. Semglee is the first interchangeable biosimilar insulin product approved by the FDA.